Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CA1 | P00915 | 6/20 | 0.64 |
| ▸ | ERN1 | O75460 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345961 | 1.00 | CA2 (0.74) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL24440799 | 0.92 | CA2 (0.65) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL14354169 | 0.92 | CA2 (0.68) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL14354170 | 0.92 | CA2 (0.68) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL24201091 | 0.92 | CA2 (0.68) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL19382909 | 0.92 | CA2 (0.68) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| Iodide SCHEMBL9768503 | 0.87 | CA2 (0.62) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL17743542 | 0.86 | CA2 (0.64) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL17743543 | 0.86 | CA2 (0.64) | CA2ALDH1A1KDM4EKMT2ACA1 | |
| SCHEMBL18719806 | 0.84 | ERN1 (0.65) | CA2ALDH1A1KDM4EKMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475762-B2 | Process for the preparation of urethanes | COVESTRO DEUTSCHLAND AG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20160152559-A1 | PROCESS FOR THE PREPARATION OF URETHANES | COVESTRO DEUTSCHLAND AG (DE) | 2016-06-02 | — | — | US | disclosed |
| US-9284267-B2 | Process for the preparation of urethanes | BAYER MATERIALSCIENCE AG (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20090275771-A1 | Process for the preparation of urethanes | COVESTRO DEUTSCHLAND AG (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2009095164-A1 | METHOD FOR PRODUCING URETHANES | BAYER MATERIALSCIENCE AG (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-1997044313-A1 | N,N'-Di(2-HYDROXYBENZYL)ETHYLENEDIAMINE-N,N'-DIACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 1997-11-27 | — | — | WO | disclosed |
| US-5281578-A | Pharmaceutical gallium metal complex in mixture with carrier | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1994-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152559-A1 | PROCESS FOR THE PREPARATION OF URETHANES | OGG1, SOD1, DUOX2 | CA2 545/4885ALDH1A1 1350/4885KDM4E 288/4885 |
| US-20090275771-A1 | Process for the preparation of urethanes | OGG1, SOD1, DUOX2 | CA2 545/4885ALDH1A1 1350/4885KDM4E 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.